HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment

Author:

Barron John J.1,Cziraky Mark J.1,Weisman Thomas2,Hicks David G.3

Affiliation:

1. HealthCore, Inc., Wilmington, Delaware, USA

2. American Imaging Management, Chicago, Illinois, USA

3. University of Rochester Medical Center, Rochester, New York, USA

Abstract

Abstract Background. Degree of physician adherence to 2001 guidelines recommending routine testing of human epidermal growth factor receptor 2 (HER2) status among newly diagnosed, recurrent, and metastatic breast cancer (BC) cases, and frequency of trastuzumab use in HER2-positive patients are not well documented. Methods. Patients newly diagnosed with BC managed by an identifiable hematologist/oncologist between June 1, 2005 and June 30, 2006 were identified from an administrative claims database of three health plans (n = 3,521). From these, a subset of 380 patients was identified for medical chart review. HER2 testing (occurrence, type of test used), HER2 status (positive, negative, unknown), and trastuzumab usage were evaluated. Results. HER2 testing occurred in 88% of all newly diagnosed patients with BC and in 98.1% of those with stage 1 or higher breast cancer (n = 322), for whom testing is recommended. Among those with HER2 testing performed (n = 335), 21.5% were positive (HER2+), 77.3% were negative (HER2−), and 1.2% were unknown. Of the 52 patients who used trastuzumab, only one patient did not have documented HER2 overexpression. Of the 45 HER2+ women who had stage 2 or higher BC, 13% did not receive trastuzumab. Conclusions. HER2 testing status was extremely high among newly diagnosed BC patients treated by hematologists/oncologists in a managed care environment. There was almost no evidence of inappropriate prescribing of trastuzumab, but 1 of every 7.5 patients with HER2-overexpressing stage 2 or higher breast cancer did not receive the agent.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference45 articles.

1. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality;Chassin;JAMA,1998

2. Healthcare Effectiveness Data & Information Set;National Committee for Quality Assurance (NCQA). HEDIS 2006;Technical Specifications,2005

3. Practice variation: implications for our health care system;Wennberg;Manag Care,2004

4. Practice guidelines: best hope for quality improvement in the 1990s;Chassin;J Occup Med,1990

Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3